PROTAC ATM degrader-1
Based on 1 Customer Validation
PROTAC ATM degrader-1 is a ATM PROTAC degrader with a KD value of 1.17 nM. PROTAC ATM degrader-1 triggers DNA damage response, cell cycle arrest, and apoptosis in cancer cells via the ubiquitin-proteasome-dependent degradation pathway. PROTAC ATM degrader-1 can be used for research on colorectal cancer.
(Pink: ATM ligand (HY-185575); Blue: VHL ligand (HY-125845); Black: linker (HY-130544)).
For research use only. We do not sell to patients.
- Purity : 98.01%
- CAS No.: 2821804-13-9
- Formula: C49H55N9O6S
- Molecular Weight:898.08
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
IC50 & Target
[1]|
ATM 1.17 nM (Kd) |
VHL |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2780 | IC50 |
3.96 μM
Compound: 9b
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| COLO 205 | IC50 |
5.11 μM
Compound: 9b
|
Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human COLO 205 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| HCT-116 | IC50 |
26.44 μM
Compound: 9b
|
Cytotoxicity against human HCT-116 cells transfected with ATM shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells transfected with ATM shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 38634707] |
| HCT-116 | IC50 |
5.82 μM
Compound: 9b
|
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| HCT-116 | IC50 |
5.82 μM
Compound: 9b
|
Cytotoxicity against human HCT-116 cells transfected with NC shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HCT-116 cells transfected with NC shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 38634707] |
| K562 | IC50 |
4.06 μM
Compound: 9b
|
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| LoVo | IC50 |
6.73 μM
Compound: 9b
|
Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human LoVo cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| NCI-H358 | IC50 |
>20 μM
Compound: 9b
|
Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human NCI-H358 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| RKO | IC50 |
3.95 μM
Compound: 9b
|
Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW13 | IC50 |
3.31 μM
Compound: 9b
|
Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW13 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW480 | IC50 |
12.12 μM
Compound: 9b
|
Cytotoxicity against human SW480 cells transfected with ATM shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells transfected with ATM shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW480 | IC50 |
2.59 μM
Compound: 9b
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW480 | IC50 |
2.59 μM
Compound: 9b
|
Cytotoxicity against human SW480 cells transfected with NC shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human SW480 cells transfected with NC shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW-620 | IC50 |
3.7 μM
Compound: 9b
|
Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW-620 | IC50 |
3.7 μM
Compound: 9b
|
Cytotoxicity against human SW620 cells transfected with NC shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human SW620 cells transfected with NC shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 38634707] |
| SW-620 | IC50 |
9.81 μM
Compound: 9b
|
Cytotoxicity against human SW620 cells transfected with ATM shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human SW620 cells transfected with ATM shRNA assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 38634707] |
In Vitro
PROTAC ATM degrader-1 (Compound 9b) (0.01-50.0 μM; 48 h) exhibits low micromolar cytotoxicity against multiple human cancer cell lines, with highest potency in SW480 (IC50 = 2.59 μM) and SW620 (IC50 = 3.70 μM) colorectal cancer cells, and shows selective toxicity against cancer cells relative to normal HIEC-6 cells[1].
PROTAC ATM degrader-1 (5-10 μM; 12 h) induces dose-dependent apoptosis in SW620 and SW480 colorectal cancer cells, with concurrent downregulation of BCL2 and upregulation of cleaved-caspase 3[1].
PROTAC ATM degrader-1 (10 μM; 12 h) alters the proteomic profile of SW620 cells, causing significant downregulation of 326 proteins including ATM, and enriching pathways related to p53 signaling, cell cycle, and apoptosis[1].
PROTAC ATM degrader-1 (5-10 μM; 12 h) induces dose-dependent G0/G1 phase arrest in SW620 colorectal cancer cells[1].
PROTAC ATM degrader-1 (2.5-10 μM; 2-24 h) activates the DNA damage response in SW620 cells, inducing dose- and time-dependent increases in p-CHK2 (Thr68) and γ-H2AX[1].
PROTAC ATM degrader-1 (0.09375-4.5 μM; 48 h) synergizes with the ATR inhibitor AZD6738 (HY-19323) to reduce cell viability in SW620 and SW480 colorectal cancer cells[1].
PROTAC ATM degrader-1 (5 μM; 12 h) in combination with ATR inhibitor AZD6738 (1 μM) enhances DNA damage in SW620 and SW480 colorectal cancer cells, as shown by increased γ-H2AX foci[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SW620, SW480 human colorectal cancer cells
-
Concentration:5 and 10 μM (apoptosis assay); 1.25, 2.5, 5 and 10 μM (Western blot confirmation)
-
Incubation Time:12 h
-
Result:Induced dose-dependent apoptosis in both cell lines: In SW620 cells, apoptosis rates were ~15% (5 μM) and ~25% (10 μM); in SW480 cells, apoptosis rates were ~20% (5 μM) and ~30% (10 μM), with all conditions showing statistically significant increases compared to the DMSO control.
Downregulated anti-apoptotic BCL2 and upregulated cleaved-caspase 3 in SW620 and SW480 cells.
-
Cell Line:SW620 human colorectal cancer cells
-
Concentration:5 and 10 μM
-
Incubation Time:12 h
-
Result:Induced dose-dependent G0/G1 phase arrest in SW620 cells: The ratio of cells in G0/G1 phase increased from ~25% (DMSO) to ~35% (5 μM) and ~40% (10 μM), while the ratio of cells in G2-M phase decreased from ~15% (DMSO) to ~10% (5 μM) and ~5% (10 μM).
-
Cell Line:SW620 human colorectal cancer cells
-
Concentration:2.5, 5 and 10 μM (dose-dependent activation); 10 μM (time-dependent activation)
-
Incubation Time:2, 4, 8, 12 and 24 h (time-dependent activation); 12 h (dose-dependent activation)
-
Result:Induced dose- and time-dependent increases in p-CHK2 (Thr68) and γ-H2AX protein levels, key biomarkers of DNA double-strand breaks and DDR activation.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude mice (female, 28−35 days old, 15 to 18 g, subcutaneously inoculated with SW620 cells)[1]
-
Dosage:15 mg/kg
-
Administration:i.p.; daily; 14 days
-
Result:Reduced tumor weight relative to the vehicle group.
Decreased ATM, BCL2, and pro-caspase 3 protein levels in tumor tissues.
Increased γ-H2AX and cleaved-caspase 3 levels in tumor tissues.
Showed no significant weight loss.
Increased γ-H2AX and cleaved-caspase 3 reactivity in tumor tissues via immunohistochemical staining.
Synergized with AZD6738 to further reduce tumor weight significantly compared to vehicle or monotherapy groups, and further increased γ-H2AX and cleaved-caspase 3 reactivity.
Chemical Information
-
CAS No. 2821804-13-9
-
Appearance Solid
-
Molecular Weight 898.08
-
Formula C49H55N9O6S
-
Color Orange to reddish brown
-
SMILES
O=C([C@H]1N(C([C@@H](NC(CCCCCN2N=NC(CCCN3C(/C(C4=C3C=CC=C4)=C5C(NC6=C/5C=CC=C6)=O)=O)=C2)=O)C(C)(C)C)=O)C[C@H](O)C1)NCC7=CC=C(C8=C(C)N=CS8)C=C7
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (111.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1135 mL | 5.5674 mL | 11.1349 mL | 27.8372 mL |
| 5 mM | 0.2227 mL | 1.1135 mL | 2.2270 mL | 5.5674 mL | |
| 10 mM | 0.1113 mL | 0.5567 mL | 1.1135 mL | 2.7837 mL | |
| 15 mM | 0.0742 mL | 0.3712 mL | 0.7423 mL | 1.8558 mL | |
| 20 mM | 0.0557 mL | 0.2784 mL | 0.5567 mL | 1.3919 mL | |
| 25 mM | 0.0445 mL | 0.2227 mL | 0.4454 mL | 1.1135 mL | |
| 30 mM | 0.0371 mL | 0.1856 mL | 0.3712 mL | 0.9279 mL | |
| 40 mM | 0.0278 mL | 0.1392 mL | 0.2784 mL | 0.6959 mL | |
| 50 mM | 0.0223 mL | 0.1113 mL | 0.2227 mL | 0.5567 mL | |
| 60 mM | 0.0186 mL | 0.0928 mL | 0.1856 mL | 0.4640 mL | |
| 80 mM | 0.0139 mL | 0.0696 mL | 0.1392 mL | 0.3480 mL | |
| 100 mM | 0.0111 mL | 0.0557 mL | 0.1113 mL | 0.2784 mL |